Yayın:
Pharmacokinetics of levamisole in the red‐eared slider turtles (Trachemys scripta elegans)

dc.contributor.authorCorum, Orhan
dc.contributor.authorDurna Corum, Duygu
dc.contributor.authorAtik, Orkun
dc.contributor.authorAltan, Feray
dc.contributor.authorEr, Ayse
dc.contributor.authorUney, Kamil
dc.date.accessioned2026-01-04T12:47:57Z
dc.date.issued2019-04-01
dc.description.abstractAbstractThe pharmacokinetics and bioavailability of levamisole were determined in red‐eared slider turtles after single intravenous (IV), intramuscular (IM), and subcutaneous (SC) administration. Nine turtles received levamisole (10 mg/kg) by each route in a three‐way crossover design with a washout period of 30 days. Blood samples were collected at time 0 (pretreatment), and at 0.25, 0.5, 1, 1.5, 3, 6, 9, 12, 18, 24, 36, and 48 hr after drug administration. Plasma levamisole concentrations were determined by a high‐performance liquid chromatography assay. Data were analyzed by noncompartmental methods. The mean elimination half‐life was 5.00, 7.88, and 9.43 hr for IV, IM, and SC routes, respectively. The total clearance and volume of distribution at steady state for the IV route were 0.14 L hr−1 kg−1 and 0.81 L/kg, respectively. For the IM and SC routes, the peak plasma concentration was 9.63 and 10.51 μg/ml, respectively, with 0.5 hr of Tmax. The bioavailability was 93.03 and 115.25% for the IM and SC routes, respectively. The IM and SC route of levamisole, which showed the high bioavailability and long t1/2ʎz, can be recommended as an effective way for treating nematodes in turtles.
dc.description.urihttps://doi.org/10.1111/jvp.12763
dc.description.urihttps://pubmed.ncbi.nlm.nih.gov/30933367
dc.description.urihttps://dx.doi.org/10.1111/jvp.12763
dc.description.urihttps://avesis.deu.edu.tr/publication/details/260bbee3-4847-42cd-bdb7-b0a25a2e0329/oai
dc.description.urihttps://hdl.handle.net/11468/17717
dc.description.urihttps://hdl.handle.net/20.500.12395/38084
dc.identifier.doi10.1111/jvp.12763
dc.identifier.eissn1365-2885
dc.identifier.endpage659
dc.identifier.issn0140-7783
dc.identifier.openairedoi_dedup___::8befd057315a543dc5d5eb923f88b39e
dc.identifier.orcid0000-0003-3168-2510
dc.identifier.orcid0000-0003-1567-991x
dc.identifier.orcid0000-0003-2411-7492
dc.identifier.orcid0000-0002-9017-763x
dc.identifier.orcid0000-0002-8674-4873
dc.identifier.pubmed30933367
dc.identifier.scopus2-s2.0-85063720229
dc.identifier.startpage654
dc.identifier.urihttps://hdl.handle.net/20.500.12597/37295
dc.identifier.volume42
dc.identifier.wos000501034000011
dc.language.isoeng
dc.publisherWiley
dc.relation.ispartofJournal of Veterinary Pharmacology and Therapeutics
dc.rightsOPEN
dc.subjectlevamisole
dc.subjectCross-Over Studies
dc.subjectBioavailability
dc.subjectAntinematodal Agents
dc.subjectInjections, Subcutaneous
dc.subjectBiological Availability
dc.subjectInjections, Intramuscular
dc.subjectTurtles
dc.subjectLevamisole
dc.subjectred-eared slider turtles
dc.subjectArea Under Curve
dc.subjectInjections, Intravenous
dc.subjectRed-Eared Slider Turtles
dc.subjectAnimals
dc.subjectPharmacokinetics
dc.subjectbioavailability
dc.subjectpharmacokinetics
dc.subjectHalf-Life
dc.subject.sdg3. Good health
dc.titlePharmacokinetics of levamisole in the red‐eared slider turtles (Trachemys scripta elegans)
dc.typeArticle
dspace.entity.typePublication
local.api.response{"authors":[{"fullName":"Orhan Corum","name":"Orhan","surname":"Corum","rank":1,"pid":{"id":{"scheme":"orcid","value":"0000-0003-3168-2510"},"provenance":null}},{"fullName":"Duygu Durna Corum","name":"Duygu","surname":"Durna Corum","rank":2,"pid":{"id":{"scheme":"orcid","value":"0000-0003-1567-991x"},"provenance":null}},{"fullName":"Orkun Atik","name":"Orkun","surname":"Atik","rank":3,"pid":{"id":{"scheme":"orcid","value":"0000-0003-2411-7492"},"provenance":null}},{"fullName":"Feray Altan","name":"Feray","surname":"Altan","rank":4,"pid":{"id":{"scheme":"orcid","value":"0000-0002-9017-763x"},"provenance":null}},{"fullName":"Ayse Er","name":"Ayse","surname":"Er","rank":5,"pid":null},{"fullName":"Kamil Uney","name":"Kamil","surname":"Uney","rank":6,"pid":{"id":{"scheme":"orcid","value":"0000-0002-8674-4873"},"provenance":null}}],"openAccessColor":null,"publiclyFunded":false,"type":"publication","language":{"code":"eng","label":"English"},"countries":null,"subjects":[{"subject":{"scheme":"keyword","value":"levamisole"},"provenance":null},{"subject":{"scheme":"keyword","value":"Cross-Over Studies"},"provenance":null},{"subject":{"scheme":"keyword","value":"Bioavailability"},"provenance":null},{"subject":{"scheme":"keyword","value":"Antinematodal Agents"},"provenance":null},{"subject":{"scheme":"keyword","value":"Injections, Subcutaneous"},"provenance":null},{"subject":{"scheme":"keyword","value":"Biological Availability"},"provenance":null},{"subject":{"scheme":"FOS","value":"04 agricultural and veterinary sciences"},"provenance":null},{"subject":{"scheme":"keyword","value":"Injections, Intramuscular"},"provenance":null},{"subject":{"scheme":"keyword","value":"Turtles"},"provenance":null},{"subject":{"scheme":"SDG","value":"3. Good health"},"provenance":null},{"subject":{"scheme":"FOS","value":"0403 veterinary science"},"provenance":null},{"subject":{"scheme":"FOS","value":"03 medical and health sciences"},"provenance":null},{"subject":{"scheme":"FOS","value":"0302 clinical medicine"},"provenance":null},{"subject":{"scheme":"keyword","value":"Levamisole"},"provenance":null},{"subject":{"scheme":"keyword","value":"red-eared slider turtles"},"provenance":null},{"subject":{"scheme":"keyword","value":"Area Under Curve"},"provenance":null},{"subject":{"scheme":"keyword","value":"Injections, Intravenous"},"provenance":null},{"subject":{"scheme":"keyword","value":"Red-Eared Slider Turtles"},"provenance":null},{"subject":{"scheme":"keyword","value":"Animals"},"provenance":null},{"subject":{"scheme":"keyword","value":"Pharmacokinetics"},"provenance":null},{"subject":{"scheme":"keyword","value":"bioavailability"},"provenance":null},{"subject":{"scheme":"keyword","value":"pharmacokinetics"},"provenance":null},{"subject":{"scheme":"keyword","value":"Half-Life"},"provenance":null}],"mainTitle":"Pharmacokinetics of levamisole in the red‐eared slider turtles (<i>Trachemys scripta elegans</i>)","subTitle":null,"descriptions":["<jats:title>Abstract</jats:title><jats:p>The pharmacokinetics and bioavailability of levamisole were determined in red‐eared slider turtles after single intravenous (<jats:styled-content style=\"fixed-case\">IV</jats:styled-content>), intramuscular (<jats:styled-content style=\"fixed-case\">IM</jats:styled-content>), and subcutaneous (<jats:styled-content style=\"fixed-case\">SC</jats:styled-content>) administration. Nine turtles received levamisole (10 mg/kg) by each route in a three‐way crossover design with a washout period of 30 days. Blood samples were collected at time 0 (pretreatment), and at 0.25, 0.5, 1, 1.5, 3, 6, 9, 12, 18, 24, 36, and 48 hr after drug administration. Plasma levamisole concentrations were determined by a high‐performance liquid chromatography assay. Data were analyzed by noncompartmental methods. The mean elimination half‐life was 5.00, 7.88, and 9.43 hr for <jats:styled-content style=\"fixed-case\">IV</jats:styled-content>,<jats:styled-content style=\"fixed-case\"> IM</jats:styled-content>, and <jats:styled-content style=\"fixed-case\">SC</jats:styled-content> routes, respectively. The total clearance and volume of distribution at steady state for the <jats:styled-content style=\"fixed-case\">IV</jats:styled-content> route were 0.14 L hr<jats:sup>−1</jats:sup> kg<jats:sup>−1</jats:sup> and 0.81 L/kg, respectively. For the <jats:styled-content style=\"fixed-case\">IM</jats:styled-content> and <jats:styled-content style=\"fixed-case\">SC</jats:styled-content> routes, the peak plasma concentration was 9.63 and 10.51 μg/ml, respectively, with 0.5 hr of <jats:italic>T</jats:italic><jats:sub>max</jats:sub>. The bioavailability was 93.03 and 115.25% for the <jats:styled-content style=\"fixed-case\">IM</jats:styled-content> and <jats:styled-content style=\"fixed-case\">SC</jats:styled-content> routes, respectively. The <jats:styled-content style=\"fixed-case\">IM</jats:styled-content> and <jats:styled-content style=\"fixed-case\">SC</jats:styled-content> route of levamisole, which showed the high bioavailability and long <jats:italic>t</jats:italic><jats:sub>1/2<jats:italic>ʎz</jats:italic></jats:sub>, can be recommended as an effective way for treating nematodes in turtles.</jats:p>"],"publicationDate":"2019-04-01","publisher":"Wiley","embargoEndDate":null,"sources":["Crossref"],"formats":["application/pdf"],"contributors":["Selcuk University Institutional Repository"],"coverages":null,"bestAccessRight":{"code":"c_abf2","label":"OPEN","scheme":"http://vocabularies.coar-repositories.org/documentation/access_rights/"},"container":{"name":"Journal of Veterinary Pharmacology and Therapeutics","issnPrinted":"0140-7783","issnOnline":"1365-2885","issnLinking":null,"ep":"659","iss":null,"sp":"654","vol":"42","edition":null,"conferencePlace":null,"conferenceDate":null},"documentationUrls":null,"codeRepositoryUrl":null,"programmingLanguage":null,"contactPeople":null,"contactGroups":null,"tools":null,"size":null,"version":null,"geoLocations":null,"id":"doi_dedup___::8befd057315a543dc5d5eb923f88b39e","originalIds":["10.1111/jvp.12763","50|doiboost____|8befd057315a543dc5d5eb923f88b39e","30933367","2925533307","50|od______2605::cb66b39c4298eb3a3cad765a7571b50e","260bbee3-4847-42cd-bdb7-b0a25a2e0329","oai:acikerisim.dicle.edu.tr:11468/17717","50|od______3346::6a2e6f90b0a5d8c5d3485b6942a852fb","50|od______4883::9549ffe3b3f9e05c071b0f303fbed1a9","oai:acikerisim.selcuk.edu.tr:20.500.12395/38084"],"pids":[{"scheme":"doi","value":"10.1111/jvp.12763"},{"scheme":"pmid","value":"30933367"},{"scheme":"handle","value":"11468/17717"},{"scheme":"handle","value":"20.500.12395/38084"}],"dateOfCollection":null,"lastUpdateTimeStamp":null,"indicators":{"citationImpact":{"citationCount":5,"influence":2.7819482e-9,"popularity":4.444455e-9,"impulse":2,"citationClass":"C5","influenceClass":"C5","impulseClass":"C5","popularityClass":"C4"}},"instances":[{"pids":[{"scheme":"doi","value":"10.1111/jvp.12763"}],"license":"Wiley Online Library User Agreement","type":"Article","urls":["https://doi.org/10.1111/jvp.12763"],"publicationDate":"2019-04-01","refereed":"peerReviewed"},{"pids":[{"scheme":"pmid","value":"30933367"}],"alternateIdentifiers":[{"scheme":"doi","value":"10.1111/jvp.12763"}],"type":"Article","urls":["https://pubmed.ncbi.nlm.nih.gov/30933367"],"publicationDate":"2020-04-28","refereed":"nonPeerReviewed"},{"alternateIdentifiers":[{"scheme":"mag_id","value":"2925533307"},{"scheme":"doi","value":"10.1111/jvp.12763"}],"type":"Article","urls":["https://dx.doi.org/10.1111/jvp.12763"],"refereed":"nonPeerReviewed"},{"alternateIdentifiers":[{"scheme":"doi","value":"10.1111/jvp.12763"}],"type":"Article","urls":["https://avesis.deu.edu.tr/publication/details/260bbee3-4847-42cd-bdb7-b0a25a2e0329/oai"],"publicationDate":"2019-11-01","refereed":"nonPeerReviewed"},{"pids":[{"scheme":"handle","value":"11468/17717"}],"alternateIdentifiers":[{"scheme":"doi","value":"10.1111/jvp.12763"}],"type":"Article","urls":["https://doi.org/10.1111/jvp.12763","https://hdl.handle.net/11468/17717"],"publicationDate":"2024-04-24","refereed":"nonPeerReviewed"},{"pids":[{"scheme":"handle","value":"20.500.12395/38084"}],"alternateIdentifiers":[{"scheme":"doi","value":"10.1111/jvp.12763"}],"type":"Article","urls":["https://doi.org/10.1111/jvp.12763","https://hdl.handle.net/20.500.12395/38084"],"publicationDate":"2019-01-01","refereed":"nonPeerReviewed"}],"isGreen":true,"isInDiamondJournal":false}
local.import.sourceOpenAire
local.indexed.atWOS
local.indexed.atScopus
local.indexed.atPubMed

Dosyalar

Koleksiyonlar